Selective splenectomy in Hodgkin's disease, stages I and II. Results of treatment

M. Berkowicz, P. Rath, E. Aghai, A. Many, I. Ben-Bassat, N. Hulu, B. Ramot, H. Brenner

Research output: Contribution to journalArticlepeer-review

Abstract

Sixty-three patients with Hodgkin's disease, in stages I or II, asymptomatic (A) or symptomatic (B), were diagnosed and followed at the Chaim Sheba Medical Center from 1969 to 1976. Only 14 were staged pathologically. Until 1971, the patients received mantle or 'inverted Y' therapy only; thereafter, an extended field that included mantle, upper abdomen and spleen irradiation was given. Symptomatic patients, as well as patients with extranodal involvement, received MOPP chemotherapy (nitrogen mustard, vincristine, procarbazine and prednisone) after termination of radiotherapy. Of 51 patients who were in stage IA or IIA, six relapsed 20 to 43 months after irradiation. Three had a pelvic recurrence: two of them were surgically staged. Thus, in only 1 of 51 patients could staging laparotomy possibly have detected pelvic disease and resulted in different therapy. Our results suggest that total nodal irradiation and staging laparotomy are not mandatory in stages IA and IIA of Hodgkin's disease. The group of 12 symptomatic patients is too small to allow us to draw definite conclusions as to the role of staging laparotomy and adjuvant chemotherapy. However, in view of the high relapse rate in the unstaged symptomatic patients, it seems that chemotherapy should be given to these patients.

Original languageEnglish
Pages (from-to)1275-1282
Number of pages8
JournalIsrael Journal of Medical Sciences
Volume14
Issue number12
StatePublished - 1978

Fingerprint

Dive into the research topics of 'Selective splenectomy in Hodgkin's disease, stages I and II. Results of treatment'. Together they form a unique fingerprint.

Cite this